Company intelligence

AEON Biopharma

Clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA), a biosimilar to Botox, for therapeutic indications like cervical dystonia and chronic migraine.

BiotechPublic · AEONIrvine, California, USAFounded 2013Public company
Last verified Sep 4, 2026

Key Metrics

Market cap
$12.01M
As of Sep 4, 2026stockanalysis.com

Company Snapshot

AEON Biopharma is a Biotech company, based in Irvine, California, USA, founded 2013. Market cap $12.01M (As of Sep 4, 2026, stockanalysis.com).

Recent changes

  1. Sep 4, 2026First reported market cap: $12.01M stockanalysis.com
  2. Jul 9, 2026AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline Pulse story

Latest Pulse

  1. AEON Biopharma, Mobix Labs S-1 Filings Test a Thin PipelineAEON Biopharma filed a fresh S-1 for a biosimilar program while Mobix Labs amended its filing disclosing a going-concern warning -- a reminder this week's IPO pipeline is mostly small-cap, not AI infrastructure.→
All 2 stories →

Coverage Timeline

newest first
  1. IPOAEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline→

All Coverage

IPO

AEON Biopharma, Mobix Labs S-1 Filings Test a Thin Pipeline

Related Companies

Same sector
Attovia TherapeuticsApnimedBraveheart BioLatigo BiotherapeuticsScribe Therapeutics
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction